Pulmonary Hypertension
-
Bilateral lung transplant comparable to heart-lung transplant in primary PAH
Recent findings reinforce the widely used strategy of bilateral lung transplantation for most patients with primary PAH who do not have structural heart disease.
-
Sotatercept in pulmonary arterial hypertension
Understanding when to consider sotatercept and how to use it has become a critical part of PAH care.
-
Bridging the gap: Mechanical circulatory support in lung transplantation for PAH
Review the need for ECLS, MCS, and ECMO in patients with PAH who are undergoing lung transplantation.
-
Third trial supports sotatercept to treat PAH
Guidelines expert James R. Klinger, MD, FCCP, said that while the evidence of efficacy is clear, more research is needed to address questions regarding the optimal duration of therapy and the potential for disease progression if therapy is stopped.
-
Experts evaluate treatment of PAH in the sotatercept era
Zeenat Safdar, MD, FCCP, reviewed recent clinical trial data on the use of the activin-signaling inhibitor sotatercept in pulmonary arterial hypertension (PAH).
-
Session to discuss the management of pulmonary disease during pregnancy
Lisa K. Moores, MD, FCCP, will present during a Tuesday afternoon session on how physiology during pregnancy alters the clinical presentation and management of pulmonary disorders.
-
Pooled data suggest sotatercept as novel disease-modifying therapy for PAH
Aaron B. Waxman, MD, PhD, FCCP, said he believes the drug will become a first-line therapy option, but questions remain regarding when to initiate treatment.
